Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarek Assi

Showing results (1-10 of 120) with videos related to

Pageof 12
Sort By:
Future Oncology (London, England)|October 4, 2019
Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?Tarek Assi
Immunotherapy|June 3, 2021
Is there a role for immune checkpoint inhibitors in chordoma?Tarek Assi
The Oncologist|August 4, 2018
"Hey Mom, Now I'm Officially an Oncologist"Tarek Assi
Immunotherapy|February 21, 2022
Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?Tarek Assi, Olivier Mir
Bulletin Du Cancer|May 21, 2019
[Challenges of breast radiologists in Lebanon]Tania Moussa, Tarek Assi
International Journal of Clinical Practice|July 5, 2021
COVID-19 pandemic shakes the trust between oncologists and their patientsJoseph Kattan, Tarek Assi
Immunotherapy|January 11, 2023
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|October 2, 2023
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|February 7, 2025
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomasTarek Assi, Axel Le Cesne
Immunotherapy|February 16, 2024
Immune checkpoint inhibitors in follicular dendritic cell sarcomaTarek Assi, Axel Le Cesne
Pageof 12

Showing results (1-10 of 120) with videos related to

Sort By:
Pageof 12
Future Oncology (London, England)|October 4, 2019
Are targeted agents the key to unlock the code for immune checkpoint inhibitors in soft-tissue sarcomas?Tarek Assi
Immunotherapy|June 3, 2021
Is there a role for immune checkpoint inhibitors in chordoma?Tarek Assi
The Oncologist|August 4, 2018
"Hey Mom, Now I'm Officially an Oncologist"Tarek Assi
Immunotherapy|February 21, 2022
Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?Tarek Assi, Olivier Mir
Bulletin Du Cancer|May 21, 2019
[Challenges of breast radiologists in Lebanon]Tania Moussa, Tarek Assi
International Journal of Clinical Practice|July 5, 2021
COVID-19 pandemic shakes the trust between oncologists and their patientsJoseph Kattan, Tarek Assi
Immunotherapy|January 11, 2023
Trabectedin and immune checkpoint inhibitors: a blissful combination or another failure in soft tissue sarcomas?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|October 2, 2023
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?Tarek Assi, Axel Le Cesne
Future Oncology (London, England)|February 7, 2025
Doxorubicin and trabectedin in leiomyosarcoma: pioneering a new era of smart combinations in soft tissue sarcomasTarek Assi, Axel Le Cesne
Immunotherapy|February 16, 2024
Immune checkpoint inhibitors in follicular dendritic cell sarcomaTarek Assi, Axel Le Cesne
Pageof 12